<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8959">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789802</url>
  </required_header>
  <id_info>
    <org_study_id>07-1026</org_study_id>
    <nct_id>NCT00789802</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC</brief_title>
  <official_title>A Randomized, Controlled Trial of Oral Naproxen and Transdermal Estradiol for Prevention of Unscheduled Bleeding in New Users of Levonorgestrel Intrauterine Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that the addition of oral naproxen or transdermal estradiol will decrease the
      number of days of unscheduled bleeding experienced by first-time users of the levonorgestrel
      intrauterine system (LNG-IUC) during the first 12 weeks of use compared to an oral placebo.
      The objective of this study is to compare the total number of days of bleeding experienced
      by first time users of the LNG-IUC randomized to oral naproxen or estradiol patch compared
      to those randomized to placebo for the first 12 weeks of use. We will enroll women
      initiating LNG-IUC to one of 3 groups, transdermal estrogen, oral naproxen or oral placebo.
      We will enroll a total of 114 women, 38 in each group. Women will keep bleeding diaries for
      16 weeks which will be used to calculate the total number of bleeding or spotting days.
      Statistical analysis will be performed to evaluate if there is less bleeding among the
      treatment arms then the placebo arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The levonorgestrel intrauterine system (LNG-IUC) is one of the most effective, reversible
      methods of contraception currently available in the United States. User satisfaction is
      overall high , however the most often cited reason for discontinuation is irregular bleeding
      . The LNG-IUC has mainly progesteronic effects on the uterine cavity. Morphological changes
      of the endometrium are observed, including stromal pseudo-decidualization and glandular
      atrophy . These endometrial changes may contribute to the irregular uterine bleeding
      experienced by women using the LNG-IUC. Up to 14% of women will discontinue the LNG-IUC
      within the 5-year period due to abnormal bleeding and up to 66% of woman who request removal
      of the LNG-IUC will do so in the first 6 months of use . Women may be less likely to
      discontinue the LNG-IUC due to abnormal bleeding patterns if they are counseled
      appropriately beforehand, however the prospect of irregular bleeding with few options for
      management may dissuade some women from even trying the LNG-IUC. A recent Cochrane review
      identified the need for further investigation into the treatment of irregular uterine
      bleeding caused by progestin only contraception .

      One treatment for progestin-induced irregular bleeding is the administration of nonsteroidal
      anti-inflammatory agents (NSAIDs). A 1999 study showed a significant decrease in the number
      of bleeding days in women using the levonorgestrel sub-dermal implant randomized to
      mefenamic acid 500 mg compared to placebo . A 2004 study found a 50% reduction in bleeding
      in depot medroxyprogesterone (DPMA) users randomized to mefenamic acid versus placebo .
      There have been no studies looking specifically at NSAIDs for the prevention or treatment of
      LNG-IUC related irregular bleeding. Naproxen is an antiprostaglandin that is commonly used
      in gynecological practice for relief of dysmenorrhea and has been used to treat menorrhagia.
      It is widely available, inexpensive, well-tolerated and has a low incidence of side effects.

      Previous studies have also shown the administration of estrogen alone and
      estrogen-containing oral contraceptives to users of subdermal levonorgestrel implants
      (NorplantÂ®) resulted in decreased frequency of irregular uterine bleeding , . A prior
      randomized, controlled trial found a 0.1mg estradiol patch resulted in the clinical
      improvement of abnormal bleeding, however this finding was not statistically significant . A
      randomized, controlled trial of DMPA users found the cyclic administration of 0.1mg
      estradiol patches did not decreases irregular menstrual bleeding . In this study, the cyclic
      use of estrogen may have resulted in lower or inconsistent serum estradiol levels.
      Additionally, the progestational mechanism of action is more similar between levonorgestrel
      subdermal implants and LNG-IUC than depot medroxyprogesterone. No study has specifically
      addressed estrogen for treatment of irregular bleeding with the LNG-IUC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Bleeding and Spotting Days</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The median number of bleeding and spotting days was 27.5 (range 5-83) in the naproxen group, 44 (2-82) in the estradiol group, and 32 (9-84) in the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Describe and Compare the Bleeding Patterns Observed in Women With a LNG-IUC Treated With Naproxen, Estradiol and Placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Level of Patient Satisfaction With the LNG-IUC at the End of the 16 Week and 12 Months Periods Between the 3 Study Groups.</measure>
    <time_frame>16 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Continuation Rates of the LNG-IUC at the End of the 16 Week and 12 Month Periods Between the 3 Study Groups</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Contraception</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>transdermal estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be randomized to transdermal estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral naproxen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be randomized to oral naproxen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>transdermal estradiol</intervention_name>
    <description>transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
    <arm_group_label>transdermal estradiol</arm_group_label>
    <other_name>Climara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
    <arm_group_label>oral naproxen</arm_group_label>
    <other_name>Naprosyn, Anaprox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo</intervention_name>
    <description>oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
    <arm_group_label>oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be of reproductive age from 18 to 45 years

          -  Must be choosing LNG-IUC for contraception

          -  Must be English-speaking

          -  Be willing to avoid additional use of exogenous hormones, such as oral
             contraceptives, for the duration of the study

          -  Be willing to avoid additional use of nonsteroidal antiinflammatory drugs, such as
             ibuprofen or aspirin for the duration of the study

          -  Be willing to comply with the study protocol, keep the bleeding diary and comply with
             follow-up visits and telephone interviews as scheduled

          -  Be willing and able to provide informed consent

        Exclusion Criteria:

          -  Known or suspected pregnancy

          -  Contraindication to estrogen use, such as presence or history of:

               -  venous thromboembolism

               -  Arterial thrombosis

               -  Thrombophilia disorders, or known family history of

               -  Hypertension

               -  Migraine headaches with aura or focal neurologic involvement, or any migraine
                  over age 35 years

          -  Recent or planned future major surgery which will result in prolonged immobilization
             during the study period

          -  Presence or history of severe hepatic disease or liver tumors

          -  Known or suspected estrogen-dependent neoplasm

          -  Vaginal bleeding of unknown etiology

          -  Any cigarette smoking and age over 35 years

          -  Contraindications to nonsteroidal anti-inflammatory use, such as presence or history
             of:

               -  Gastrointestinal ulcer disease

               -  Renal insufficiency or failure

               -  Aspirin-induced asthma or hypersensitivity reaction

               -  Systemic lupus erythematosus (SLE) and mixed connective tissue disorders

               -  Use of anticoagulants

               -  Cardiovascular disease

          -  Use of medications that alter estrogen metabolism, i.e. rifampin, certain
             anti-seizure medications

          -  Regular use of an NSAID

          -  Current diagnosis of menorrhagia, metrorrhagia, symptomatic uterine fibroids, or
             endometrial polyp

          -  Hypersensitivity or allergy to any of the components of the estradiol patch

          -  Use of injectable contraception within 6 months of the start of the study medication

          -  Delivery or abortion in the previous 4 weeks

          -  Prior use of LNG-IUD

          -  Any condition, that in the opinion of the investigator, would contraindicate study
             participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tessa E Madden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School fo Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 8, 2014</lastchanged_date>
  <firstreceived_date>November 11, 2008</firstreceived_date>
  <firstreceived_results_date>June 27, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Tessa Madden, MD</investigator_full_name>
    <investigator_title>Asst. Professor</investigator_title>
  </responsible_party>
  <keyword>contraception</keyword>
  <keyword>progestin contraception</keyword>
  <keyword>intrauterine contraception</keyword>
  <keyword>unscheduled bleeding</keyword>
  <keyword>placebo</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>129 participants were recruited from November 2008 to January 2010 and follow-up was conducted through May 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Naproxen</title>
          <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Oral Placebo</title>
          <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
        </group>
        <group group_id="P3">
          <title>Transdermal Estradiol</title>
          <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Naproxen</title>
          <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Oral Placebo</title>
          <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
        </group>
        <group group_id="B3">
          <title>Transdermal Estradiol</title>
          <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="43"/>
                <measurement group_id="B4" value="129"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="43"/>
                <measurement group_id="B4" value="129"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26.3" spread="4.7"/>
                <measurement group_id="B2" value="25" spread="4.2"/>
                <measurement group_id="B3" value="26.2" spread="5.1"/>
                <measurement group_id="B4" value="25.8" spread="4.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="43"/>
                <measurement group_id="B4" value="129"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="42"/>
                <measurement group_id="B3" value="43"/>
                <measurement group_id="B4" value="129"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Bleeding and Spotting Days</title>
        <description>The median number of bleeding and spotting days was 27.5 (range 5-83) in the naproxen group, 44 (2-82) in the estradiol group, and 32 (9-84) in the placebo group.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Oral Naproxen</title>
            <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
          </group>
          <group group_id="O3">
            <title>Transdermal Estradiol</title>
            <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Bleeding and Spotting Days</title>
            <description>The median number of bleeding and spotting days was 27.5 (range 5-83) in the naproxen group, 44 (2-82) in the estradiol group, and 32 (9-84) in the placebo group.</description>
            <units>DAYS</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="27.5" lower_limit="5" upper_limit="83"/>
                  <measurement group_id="O2" value="32" lower_limit="9" upper_limit="84"/>
                  <measurement group_id="O3" value="44" lower_limit="2" upper_limit="82"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe and Compare the Bleeding Patterns Observed in Women With a LNG-IUC Treated With Naproxen, Estradiol and Placebo.</title>
        <time_frame>16 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Level of Patient Satisfaction With the LNG-IUC at the End of the 16 Week and 12 Months Periods Between the 3 Study Groups.</title>
        <time_frame>16 week</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare Continuation Rates of the LNG-IUC at the End of the 16 Week and 12 Month Periods Between the 3 Study Groups</title>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Naproxen</title>
          <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Oral Placebo</title>
          <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
        </group>
        <group group_id="E3">
          <title>Transdermal Estradiol</title>
          <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tessa Madden</name_or_title>
      <organization>Washington University</organization>
      <phone>3147471331</phone>
      <email>maddent@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
